Lvr, a Signaling System That Controls Global Gene Regulation and Virulence in Pathogenic Leptospira
Leptospirosis is an emerging zoonotic disease with more than 1 million cases annually. Currently there is lack of evidence for signaling pathways involved during the infection process of . In our comprehensive genomic analysis of 20 spp. we identified seven pathogen-specific Two-Component System (TC...
Gespeichert in:
Veröffentlicht in: | Frontiers in cellular and infection microbiology 2018-02, Vol.8, p.45-45 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Leptospirosis is an emerging zoonotic disease with more than 1 million cases annually. Currently there is lack of evidence for signaling pathways involved during the infection process of
. In our comprehensive genomic analysis of 20
spp. we identified seven pathogen-specific Two-Component System (TCS) proteins. Disruption of two these TCS genes in pathogenic
strain resulted in loss-of-virulence in a hamster model of leptospirosis. Corresponding genes
and
) are juxtaposed in an operon and are predicted to encode a hybrid histidine kinase and a hybrid response regulator, respectively. Transcriptome analysis of
mutant strains with disruption of one (
) or both genes (
) revealed global transcriptional regulation of 850 differentially expressed genes. Phosphotransfer assays demonstrated that LvrA phosphorylates LvrB and predicted further signaling downstream to one or more DNA-binding response regulators, suggesting that it is a branched pathway. Phylogenetic analyses indicated that
and
evolved independently within different ecological lineages in
via gene duplication. This study uncovers a novel-signaling pathway that regulates virulence in pathogenic
(Lvr), providing a framework to understand the molecular bases of regulation in this life-threatening bacterium. |
---|---|
ISSN: | 2235-2988 2235-2988 |
DOI: | 10.3389/fcimb.2018.00045 |